Standard Biotools (LAB) Cash from Financing Activities (2010 - 2026)
Standard Biotools (LAB) posted quarterly Cash from Financing Activities of -$40000.0 for Q1 2026, up 13.04% year-over-year from -$35384.6 in Q1 2025, and down 106.45% quarter-over-quarter from $620000.0 in Q4 2025.
Standard Biotools (LAB) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Standard Biotools (LAB) has reported Cash from Financing Activities for 17 consecutive years, with -$40000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 13.04% year-over-year to -$40000.0; the TTM figure through Mar 2026 stood at $576000.0 (up 100.69% YoY), while the FY2025 annual figure was $570000.0, up 100.56% from the prior year.
- Cash from Financing Activities retreated to -$40000.0 in Q1 2026 per LAB's latest filing, from $620000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $213.0 million in Q2 2022 and bottomed at -$54.5 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged $7.2 million across 5 years, with a median of -$112000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 18474.29% — and 2023, when it plunged 23180.0%.
- Standard Biotools' Cash from Financing Activities stood at -$270000.0 in 2022, then plunged by 271.48% to -$1.0 million in 2023, then tumbled by 5335.69% to -$54.5 million in 2024, then surged by 101.14% to $620000.0 in 2025, then sank by 106.45% to -$40000.0 in 2026.
- Business Quant data shows LAB's Cash from Financing Activities at -$40000.0 in Q1 2026, $620000.0 in Q4 2025, and -$112000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.75 Bn | 194.14 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.36 Bn | 123.88 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.20 Bn | 72.66 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 52.10 Bn | 47.85 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.77 Bn | 31.66 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Standard Biotools | 252.98 Mn | -223.74 Mn | 10.54 Mn | -138,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -138,000.00 |
| Jun 30, 2026 | -138,000.00 |
| Mar 31, 2026 | -40,000.00 |
| Mar 31, 2026 | -40,000.00 |
| Dec 31, 2025 | 620,000.00 |
| Dec 31, 2025 | 620,000.00 |
| Sep 30, 2025 | -112,000.00 |
| Sep 30, 2025 | -112,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Dec 31, 2024 | -54.52 Mn |
| Dec 31, 2024 | -54.52 Mn |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -28.36 Mn |
| Jun 30, 2024 | -28.36 Mn |
| Mar 31, 2024 | -19.73 Mn |
| Mar 31, 2024 | -19.73 Mn |